Table 1

Chemotherapy, tumor characteristics, levels of apoptosis, and clinical responses

Patients were treated with the indicated primary regimens before surgery.

Patient1st chemoCyclesDose2nd chemoCyclesERaPRHer2Path. responseClin. responseApoptosis baselineApoptosis 24 hApoptosis 48 h
1wk taxol12175FAC4posnegnegCRPR0.80%0.98%9.12%
2AT460/60noneposposnaCRCR3.88%4.18%36.89%
3AT460/60nonenegposposCRnear CR0.33%nd9.61%
4AT460/60nonenegnegneg<1 cmPR2.09%1.60%6.84%
5AT460/60nonenegposunk<1 cmPR0.81%nd11.89%
6AT460/60nonenegnegneg<1 cmPR0.02%1.31%3.46%
7AT660/60noneposnegpos<1 cmPR0.06%11.91%nd
8AT460/60noneposnegna<1 cmPR4.59%2.09%12.18%
9AT660/60CMF3negnegneg3 cmPR0.99%1.20%nd
10taxol q34175FAC4pospospos2 cmnear CR0.29%0.24%0.21%
11AT660/60noneposposneg5.3 cmPR0.30%6.13%3.52%
12AT460/60nonenegposneg4 cmPR0.14%1.03%0.01%
13wk taxol1260/60FAC4negnegneg1.4 cmPR1.22%10.68%0.88%
14AT460/60nonenegnegposprogressedprogressed0.60%0.06%0.50%
15wk taxol1280FAC4posposnegprogressedprogressed0.72%nd0.84%
  • a ER, estrogen receptor; PR, progesterone receptor; CMF, cyclophosphamide/methotrexate/5-fluorouracil; q3, 3-weekly.